Zenas BioPharma Inc.(ZBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZBIO Zenas BioPharma Inc.

盘后交易 12-15 19:54:51 EST

32.59

-8.00

-19.71%

盘后31.50

-1.09-3.34%

19:14 EST

最高41.10	最低31.51	成交量55.89万
今开40.57	昨收40.59	日振幅23.63%
总市值17.49亿	流通市值6.87亿	总股本5,368万
成交额1,937万	换手率2.65%	流通股本2,107万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":32.59,"timestamp":1765832400000,"preClose":40.59,"halted":0,"volume":558881,"hourTrading":{"tag":"盘后","latestPrice":31.5,"preClose":32.59,"latestTime":"19:14 EST","volume":1573,"amount":51197.698838000004,"timestamp":1765844071372},"delay":0,"floatShares":21071865,"shares":53679166,"eps":-4.527832,"marketStatus":"盘后交易","change":-8,"latestTime":"12-15 19:54:51 EST","open":40.57,"high":41.0999,"low":31.51,"amount":19370955.18025,"amplitude":0.236263,"askPrice":32.58,"askSize":16,"bidPrice":31.5,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-4.527832,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765846800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":40.59,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":40.9,"preClose":40.59,"latestTime":"08:40 EST","volume":304,"amount":12466.189408,"timestamp":1765806000923},"postHourTrading":{"tag":"盘后","latestPrice":31.5,"preClose":32.59,"latestTime":"19:14 EST","volume":1573,"amount":51197.698838000004,"timestamp":1765844071372},"volumeRatio":2.163065,"impliedVol":1.0649,"impliedVolPercentile":0.7941},"requestUrl":"/m/hq/s/ZBIO/wiki","defaultTab":"wiki","newsList":[{"id":"1133394639","title":"InnoCare Pharma宣布Orelabrutinib（Btk抑制剂）在系统性红斑狼疮的2B期研究中实现主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1133394639","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133394639?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:07","pubTimestamp":1765800457,"startTime":"0","endTime":"0","summary":"InnoCare Pharma宣布在针对系统性红斑狼疮的Orelabrutinib（Btk抑制剂）2B期研究中实现了主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1142056905","title":"Zenas BioPharma：Obexelimab三期Indigo试验在免疫球蛋白G4相关疾病（IgG4-RD）中的初步结果预计将在年末公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1142056905","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142056905?lang=zh_cn&edition=full","pubTime":"2025-11-12 20:13","pubTimestamp":1762949593,"startTime":"0","endTime":"0","summary":"Zenas BioPharma：Obexelimab三期Indigo试验在免疫球蛋白G4相关疾病（IgG4-RD）中的初步结果预计将在年末公布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1122038621","title":"Zenas Biopharma公布Obexelimab在复发性多发性硬化症II期Moonstone试验中取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1122038621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122038621?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:08","pubTimestamp":1761563296,"startTime":"0","endTime":"0","summary":"Zenas Biopharma公布Obexelimab在复发性多发性硬化症II期Moonstone试验中取得积极结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1165438252","title":"Zenas Biopharma预计将在2026年第一季度启动Orelabrutinib针对继发渐进性多发性硬化症患者的全球三级临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1165438252","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165438252?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:08","pubTimestamp":1761563293,"startTime":"0","endTime":"0","summary":"Zenas Biopharma预计将在2026年第一季度启动Orelabrutinib针对继发渐进性多发性硬化症患者的全球三级临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1122167777","title":"Zenas Biopharma向SEC申请最多出售630万股普通股的架构筹资","url":"https://stock-news.laohu8.com/highlight/detail?id=1122167777","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122167777?lang=zh_cn&edition=full","pubTime":"2025-10-22 04:49","pubTimestamp":1761079748,"startTime":"0","endTime":"0","summary":"Zenas Biopharma向SEC申请最多出售630万股普通股，出售股东为卖方。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1182685701","title":"Zenas BioPharma：市场发行招股说明书 涵盖根据销售协议可能发行的最多2亿美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1182685701","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182685701?lang=zh_cn&edition=full","pubTime":"2025-10-09 04:37","pubTimestamp":1759955838,"startTime":"0","endTime":"0","summary":"Zenas BioPharma：市场发行招股说明书 涵盖根据销售协议可能发行的最多2亿美元普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1146091822","title":"Zenas BioPharma Inc.新型口服IL-17AA/AF抑制剂和口服透脑TYK2抑制剂预计2026年启动一期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1146091822","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146091822?lang=zh_cn&edition=full","pubTime":"2025-10-08 17:06","pubTimestamp":1759914392,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc.的新型口服IL-17AA/AF抑制剂和口服透脑TYK2抑制剂预计将于2026年开始一期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK4139","BK0239","ZBIO"],"gpt_icon":0},{"id":"1121287790","title":"Zenas BioPharma Inc.与诺诚健华宣布签署许可协议，授予Zenas三项自身免疫候选产品的权益，其中包括BTK抑制剂奥雷巴替尼，该药物正处于多发性硬化症三期临床开发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1121287790","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121287790?lang=zh_cn&edition=full","pubTime":"2025-10-08 17:00","pubTimestamp":1759914020,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc.与诺诚健华宣布签署许可协议，授予Zenas三项自身免疫候选产品的权益，其中包括BTK抑制剂奥雷巴替尼，该药物正处于多发性硬化症三期临床开发阶段","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK0239","BK4139","688428"],"gpt_icon":0},{"id":"1170408200","title":"诺诚健华表示总支付款项连同研发、监管里程碑及商业化里程碑付款超过20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170408200","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170408200?lang=zh_cn&edition=full","pubTime":"2025-10-08 16:58","pubTimestamp":1759913894,"startTime":"0","endTime":"0","summary":"诺诚健华宣布，包括研发里程碑付款、监管里程碑付款和商业化里程碑付款在内的总支付款项已超过20亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","ZBIO","BK4139","688428"],"gpt_icon":0},{"id":"1136169257","title":"异动解读 | 生物科技新星Zenas BioPharma首秀大涨11.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136169257","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136169257?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:00","pubTimestamp":1726246829,"startTime":"0","endTime":"0","summary":"今日,生物科技公司Zenas BioPharma Inc. 在纳斯达克成功完成IPO,股价大涨11.71%,引发市场关注。当日Zenas IPO发行价为17美元,开盘股价则为18.35美元,较发行价溢价8%。Zenas在本次IPO中发行1320万股,募集资金2.25亿美元,超过了原计划规模。随着美国IPO新股市场近期回温,投资者对Zenas这样前景可期的生物科技股青睐有加,均有望成为推动其当日首秀股价大涨的重要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZBIO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zenasbio.com","stockEarnings":[{"period":"1week","weight":0.0307},{"period":"1month","weight":0.1338},{"period":"3month","weight":1.0064},{"period":"6month","weight":2.9293},{"period":"1year","weight":3.3881},{"period":"ytd","weight":3.956}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Zenas BioPharma, Inc.最初于2019年11月12日在开曼注册成立，名称为Zenas BioPharma（开曼）Limited。2023年8月2日，该公司在特拉华州成立，同时将其名称从Zenas BioPharma（Cayman）Limited更改为Zenas BioPharma, Inc.。他们是一家临床阶段的全球生物制药公司，致力于为有需要的患者开发和商业化基于免疫的变革疗法。随着对自身免疫性疾病发病机制的不断了解，以及有前景的基于免疫学的药理学靶点的扩展，他们正在建立一家专注于免疫学和炎症（“I&I”）的生物制药公司。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.066193},{"month":2,"riseRate":0.4,"avgChangeRate":-0.014847},{"month":3,"riseRate":0.6,"avgChangeRate":-0.027723},{"month":4,"riseRate":0.5,"avgChangeRate":0.001823},{"month":5,"riseRate":0.75,"avgChangeRate":0.218705},{"month":6,"riseRate":0.25,"avgChangeRate":-0.082782},{"month":7,"riseRate":0.2,"avgChangeRate":-0.126333},{"month":8,"riseRate":0.6,"avgChangeRate":0.033743},{"month":9,"riseRate":0.5,"avgChangeRate":0.044898},{"month":10,"riseRate":0.6,"avgChangeRate":0.128289},{"month":11,"riseRate":0,"avgChangeRate":-0.164546},{"month":12,"riseRate":0.4,"avgChangeRate":0.053544}],"exchange":"NASDAQ","name":"Zenas BioPharma Inc.","nameEN":"Zenas BioPharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zenas BioPharma Inc.(ZBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Zenas BioPharma Inc.(ZBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Zenas BioPharma Inc.,ZBIO,Zenas BioPharma Inc.股票,Zenas BioPharma Inc.股票老虎,Zenas BioPharma Inc.股票老虎国际,Zenas BioPharma Inc.行情,Zenas BioPharma Inc.股票行情,Zenas BioPharma Inc.股价,Zenas BioPharma Inc.股市,Zenas BioPharma Inc.股票价格,Zenas BioPharma Inc.股票交易,Zenas BioPharma Inc.股票购买,Zenas BioPharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zenas BioPharma Inc.(ZBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Zenas BioPharma Inc.(ZBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}